Human Metabolome Technologies Adjusts Valuation Metrics Amidst Mixed Financial Performance

Human Metabolome Technologies, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation metrics, which are critical indicators of its market position and financial health.
The stock's P/E ratio stands at 16, while the Price to Book Value is noted at 2.30. Additionally, the company reports an EV to EBIT of 10.36 and an EV to EBITDA of 7.95. The EV to Sales ratio is recorded at 2.23, and the PEG ratio is 1.46. Notably, the company has demonstrated a robust Return on Capital Employed (ROCE) of 50.66% and a Return on Equity (ROE) of 14.19%, indicating effective utilization of capital and shareholder equity.

Despite a challenging quarter in June 2025, where financial performance was notably negative, the stock has managed to generate an 18.59% return over the past year, with profits increasing by 11.2%. This context provides a comprehensive view of Human Metabolome Technologies, Inc.'s current standing in the market.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.